Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40410
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gyselinck, I | - |
dc.contributor.author | Liesenborghs, L. | - |
dc.contributor.author | Belmans, Ann | - |
dc.contributor.author | Engelen, MM | - |
dc.contributor.author | Betrains, A | - |
dc.contributor.author | Van Thillo, Q | - |
dc.contributor.author | Nguyen, PAH | - |
dc.contributor.author | Goeminne, P | - |
dc.contributor.author | Soenen, AC | - |
dc.contributor.author | De Maeyer, N | - |
dc.contributor.author | Pilette, C | - |
dc.contributor.author | Papleux, E | - |
dc.contributor.author | Vanderhelst, E | - |
dc.contributor.author | Derweduwen, A | - |
dc.contributor.author | Alexander, P | - |
dc.contributor.author | Bouckaert, B. | - |
dc.contributor.author | Martinot, JB | - |
dc.contributor.author | Decoster, L | - |
dc.contributor.author | Vandeurzen, K | - |
dc.contributor.author | Schildermans, R | - |
dc.contributor.author | Verhamme, P | - |
dc.contributor.author | Janssens, W. | - |
dc.contributor.author | VOS, R. | - |
dc.date.accessioned | 2023-06-15T08:01:09Z | - |
dc.date.available | 2023-06-15T08:01:09Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2023-06-09T10:42:05Z | - |
dc.identifier.citation | ERJ Open Research, 8 (1) (Art N° 00610-2021) | - |
dc.identifier.uri | http://hdl.handle.net/1942/40410 | - |
dc.description.abstract | Background and objectives Azithromycin was rapidly adopted as a repurposed drug to treat coronavirus disease 2019 (COVID-19) early in the pandemic. We aimed to evaluate its efficacy in patients hospitalised for COVID-19.Methods In a series of randomised, open-label, phase 2 proof-of-concept, multicentre clinical trials (Direct Antivirals Working against the novel coronavirus (DAWn)), several treatments were compared with standard of care. In 15 Belgian hospitals, patients hospitalised with moderate to severe COVID-19 were allocated 2:1 to receive standard of care plus azithromycin or standard of care alone. The primary outcome was time to live discharge or sustained clinical improvement, defined as a two-point improvement on the World Health Organization (WHO) ordinal scale sustained for at least 3 days.Results Patients were included between April 22 and December 17, 2020. When 15-day follow-up data were available for 160 patients (56% of preset cohort), an interim analysis was performed at request of the independent Data Safety and Monitoring Board. Subsequently, DAWn-AZrTHRO was stopped for futility. In total, 121 patients were allocated to the treatment arm and 64 patients to the standard-of-care arm. We found no effect of azithromycin on the primary outcome with a hazard ratio of 1.044 (95% CI 0.772-1.413; p=0.7798). None of the predefined subgroups showed significant interaction as covariates in the Fine-Gray regression analysis. No benefit of azithromycin was found on any of the short- and longer-term secondary outcomes.Conclusion Time to clinical improvement is not influenced by azithromycin in patients hospitalised with moderate to severe COVID-19. | - |
dc.language.iso | en | - |
dc.publisher | EUROPEAN RESPIRATORY SOC JOURNALS LTD | - |
dc.title | Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO) | - |
dc.type | Journal Contribution | - |
dc.identifier.issue | 1 | - |
dc.identifier.volume | 8 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.artnr | 00610-2021 | - |
local.class | dsPublValOverrule/internal_author_not_expected | - |
dc.identifier.doi | 10.1183/23120541.00610-2021 | - |
dc.identifier.isi | 000783165900061 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | no | - |
item.fullcitation | Gyselinck, I; Liesenborghs, L.; Belmans, Ann; Engelen, MM; Betrains, A; Van Thillo, Q; Nguyen, PAH; Goeminne, P; Soenen, AC; De Maeyer, N; Pilette, C; Papleux, E; Vanderhelst, E; Derweduwen, A; Alexander, P; Bouckaert, B.; Martinot, JB; Decoster, L; Vandeurzen, K; Schildermans, R; Verhamme, P; Janssens, W. & VOS, R. (2022) Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO). In: ERJ Open Research, 8 (1) (Art N° 00610-2021). | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
item.contributor | Gyselinck, I | - |
item.contributor | Liesenborghs, L. | - |
item.contributor | Belmans, Ann | - |
item.contributor | Engelen, MM | - |
item.contributor | Betrains, A | - |
item.contributor | Van Thillo, Q | - |
item.contributor | Nguyen, PAH | - |
item.contributor | Goeminne, P | - |
item.contributor | Soenen, AC | - |
item.contributor | De Maeyer, N | - |
item.contributor | Pilette, C | - |
item.contributor | Papleux, E | - |
item.contributor | Vanderhelst, E | - |
item.contributor | Derweduwen, A | - |
item.contributor | Alexander, P | - |
item.contributor | Bouckaert, B. | - |
item.contributor | Martinot, JB | - |
item.contributor | Decoster, L | - |
item.contributor | Vandeurzen, K | - |
item.contributor | Schildermans, R | - |
item.contributor | Verhamme, P | - |
item.contributor | Janssens, W. | - |
item.contributor | VOS, R. | - |
item.validation | ecoom 2023 | - |
crisitem.journal.eissn | 2312-0541 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
00610-2021.full.pdf | Published version | 830.34 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.